Cerebrolysin
Also known as: FPF-1070
Cerebrolysin is a mixture of peptides and amino acids derived from pig brain tissue, studied for reported neuroprotective effects. It is used in some countries but is not approved for human use in Australia.
- Category
- Cognitive / Nootropic
- Reported half-life
- Not well established
- Common forms
- Injectable solution (overseas medical preparations)
- Research status
- Marketed and used in several countries (e.g. parts of Europe and Asia) for neurological conditions; not approved for human use in Australia. Clinical trial results are mixed and debated.
- Last updated
- 21 June 2026
Claimed effects
The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.
- Reported to have neuroprotective and neurotrophic effects in some studies
- Studied for possible effects in stroke and dementia populations
- Reported to influence neuronal repair and plasticity
- Reported to mimic the action of endogenous neurotrophic factors
How it is reported to work
Cerebrolysin is a standardised mixture of low-molecular-weight peptides and free amino acids prepared from porcine brain protein. It is proposed to act in a neurotrophic factor-like manner, reportedly supporting neuronal survival, repair and plasticity. The exact mechanism is not fully defined, and reported clinical effects across studies have been mixed.
Background
Cerebrolysin is a peptide and amino acid mixture derived from purified pig brain protein. It has been used in some countries for neurological conditions such as stroke and dementia. This page is educational information, not medical advice, and the effects below are reported claims, not established facts.
What the research shows
Cerebrolysin has been studied in a number of clinical trials, but results across the literature are mixed and debated, with reviews reaching differing conclusions. The evidence is not settled, and its status varies by country.
| Evidence type | Status |
|---|---|
| Clinical trials (overseas) | Present but mixed |
| Consistent international consensus | Lacking |
| Australian approval | None |
What people use it for (reported)
Online, people report interest in Cerebrolysin for cognition and recovery after neurological events. These are anecdotal or off-label reports, not validated outcomes for general use. Reported benefits should not be read as proven, and nothing here is encouragement to use it.
Things to be aware of
Cerebrolysin is not approved for human use in Australia. As an animal-derived biological product it raises particular questions about identity, purity and immune reactions, and grey-market preparations cannot be verified by consumers. If you have a neurological concern, the appropriate step is to consult a qualified healthcare professional. This article does not recommend obtaining or using Cerebrolysin.
Reported positives & side effects
Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.
Reported positives
- Reported neuroprotective and neurotrophic effects in some studies
- Reported interest in stroke and dementia recovery research
- Reported support for neuronal repair and plasticity
- Reported subjective improvements in clarity by some users
Common side effects
- Injection-site reactions reported
- Headache or dizziness reported
- Feeling hot, sweating or flushing reported
- Mild agitation or restlessness reported
Rare / serious side effects
- Allergic or hypersensitivity reactions reported, given the animal-derived origin
- Seizures reported rarely in susceptible individuals
- Infection or immunological reaction from unverified grey-market product
- Unknown effects from contaminated or non-standardised preparations
Reported misuse & overdose risks
What has been reported to happen with overuse, excessive dosing, or long-term misuse of Cerebrolysin. Listed so you can make an informed decision, not to suggest any use is safe.
- Reported self-administered injection of an animal-derived biological without medical oversight
- Reported use of unverified grey-market vials with uncertain sterility and identity
- Reported dosing courses beyond those used in clinical studies
- Reported self-treatment of serious neurological conditions in place of professional care
Reported results timeline
Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. Reported effects are described as gradual over a multi-week injection course, though clinical results across studies are mixed.
First effects
Reported subtle alertness changes within days of a course
Noticeable change
Reported cognitive or mood shifts over one to two weeks
Clear results
Reported cumulative effects over a multi-week course, though evidence is mixed
Commonly reported dosing & protocol
Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take Cerebrolysin. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.
| Route | Intramuscular or intravenous (pre-mixed ampoule solution; no reconstitution) |
|---|---|
| Typical reported dose | Reported as roughly 5-10 mL per day in study settings |
| Frequency | Reported as once daily during a course |
| Cycle length | Reported as daily courses over several weeks, sometimes repeated periodically |
Commonly reported in studies as daily intravenous or intramuscular courses over several weeks, sometimes repeated; reported patterns vary. This is reported information, not advice.
Best used with / commonly stacked with
Combinations people report using together. Reported, not recommended, stacking can increase risks.
Safety notes
Cerebrolysin is not approved for human use in Australia, and as an animal-derived biological product it carries particular identity, purity and immunological considerations. Reported clinical evidence is mixed and contested. Anyone with a neurological concern should consult a qualified healthcare professional rather than self-experiment.